Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity
- PMID: 33733768
- PMCID: PMC8041306
- DOI: 10.1021/acs.jmedchem.0c02223
Structure-Activity Relationship Studies on Oxazolo[3,4- a]pyrazine Derivatives Leading to the Discovery of a Novel Neuropeptide S Receptor Antagonist with Potent In Vivo Activity
Abstract
Neuropeptide S modulates important neurobiological functions including locomotion, anxiety, and drug abuse through interaction with its G protein-coupled receptor known as neuropeptide S receptor (NPSR). NPSR antagonists are potentially useful for the treatment of substance abuse disorders against which there is an urgent need for new effective therapeutic approaches. Potent NPSR antagonists in vitro have been discovered which, however, require further optimization of their in vivo pharmacological profile. This work describes a new series of NPSR antagonists of the oxazolo[3,4-a]pyrazine class. The guanidine derivative 16 exhibited nanomolar activity in vitro and 5-fold improved potency in vivo compared to SHA-68, a reference pharmacological tool in this field. Compound 16 can be considered a new tool for research studies on the translational potential of the NPSergic system. An in-depth molecular modeling investigation was also performed to gain new insights into the observed structure-activity relationships and provide an updated model of ligand/NPSR interactions.
Conflict of interest statement
The authors declare no competing financial interest.
Figures









Similar articles
-
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68).J Med Chem. 2011 Apr 28;54(8):2738-44. doi: 10.1021/jm200138r. Epub 2011 Apr 5. J Med Chem. 2011. PMID: 21466221 Free PMC article.
-
Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor.J Pharmacol Exp Ther. 2008 Jun;325(3):893-901. doi: 10.1124/jpet.107.135103. Epub 2008 Mar 12. J Pharmacol Exp Ther. 2008. PMID: 18337476 Free PMC article.
-
Synthesis, structure-activity relationship studies, and identification of novel 5,6,7,8-tetrahydroimidazo[1,5-a]pyrazine derivatives as dual orexin receptor antagonists. Part 1.Bioorg Med Chem Lett. 2013 Apr 1;23(7):2212-6. doi: 10.1016/j.bmcl.2013.01.088. Epub 2013 Jan 29. Bioorg Med Chem Lett. 2013. PMID: 23434414
-
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.Med Res Rev. 2010 Sep;30(5):751-77. doi: 10.1002/med.20180. Med Res Rev. 2010. PMID: 19824051 Review.
-
Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. doi: 10.1080/13543776.2017.1254195. Epub 2016 Nov 9. Expert Opin Ther Pat. 2017. PMID: 27788040 Review.
Cited by
-
Enantioselective β-C(sp3)-H Nucleophilic Tosylation of Native Amides: A Synthetic Platform for Chiral Methyl Stereocenters.J Am Chem Soc. 2025 Jun 11;147(23):19559-19567. doi: 10.1021/jacs.4c17267. Epub 2025 May 31. J Am Chem Soc. 2025. PMID: 40448573 Free PMC article.
-
Roles of Neuropeptide S in Anesthesia, Analgesia, and Sleep.Pharmaceuticals (Basel). 2021 May 19;14(5):483. doi: 10.3390/ph14050483. Pharmaceuticals (Basel). 2021. PMID: 34069327 Free PMC article. Review.
-
Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia.Brain Sci. 2022 Jun 11;12(6):768. doi: 10.3390/brainsci12060768. Brain Sci. 2022. PMID: 35741653 Free PMC article.
-
Relationship of Neuropeptide S (NPS) with Neurocognitive, Clinical, and Electrophysiological Parameters of Patients during Structured Rehabilitation Therapy for Schizophrenia.J Clin Med. 2022 Sep 6;11(18):5266. doi: 10.3390/jcm11185266. J Clin Med. 2022. PMID: 36142912 Free PMC article.
-
Pharmacology, Physiology and Genetics of the Neuropeptide S System.Pharmaceuticals (Basel). 2021 Apr 23;14(5):401. doi: 10.3390/ph14050401. Pharmaceuticals (Basel). 2021. PMID: 33922620 Free PMC article. Review.
References
-
- Syuji S.; Yasushi S.; Nobuyuki M.; Koji Y.. cDNA and protein sequence of a novel human and animal G protein-coupled receptors and their uses in drug screening, diagnosis, and therapeutics. WO2002031145A1, April 18, 2002.
-
- Xu Y.-L.; Reinscheid R. K.; Huitron-Resendiz S.; Clark S. D.; Wang Z.; Lin S. H.; Brucher F. A.; Zeng J.; Ly N. K.; Henriksen S. J.; de Lecea L.; Civelli O. Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 2004, 43, 487–497. 10.1016/j.neuron.2004.08.005. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information